Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
Anoro Ellipta 20 mcg
has been added to your basket
The receptor binding affinity of a treatment is an important characteristic in its ability to provide a medicinal benefit, particularly when it comes to anti-inflammatory effect.3
Both fluticasone furoate and vilanterol are associated with high receptor binding affinities.*2,3
Of course, therapeutic index does not just consider a treatment’s receptor binding affinity though – systemic effects are considered too.1
Relvar’s ICS treats underlying inflammation, with more airway protection and less systemic effect vs budesonide.*1
20% cortisol suppression is the lowest boundary of detectable systemic exposure for corticosteroids, after which systemic adverse events become more likely.3
This graph has been independently created by GSK from the original data. The same results were first published in Daley-Yates P, et al. Br J Clin Pharmacol 2020;1–11.
Fluticasone furoate is not licensed as a monotherapy in asthma in all markets.
High lipophilicity and tissue permeability1
Low solubility and slow inhaled drug particle dissolution1
High affinity for, and slow dissociation from, the GR1